ALIGOS THERAPEUTICS INC's ticker is ALGS and the CUSIP is 01626L105. A total of 47 filers reported holding ALIGOS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $472,020 | -23.1% | 631,887 | 0.0% | 0.14% | -24.7% |
Q2 2023 | $613,562 | +11.1% | 631,887 | 0.0% | 0.19% | -16.7% |
Q1 2023 | $552,269 | +677.8% | 631,887 | +982.1% | 0.23% | +936.4% |
Q2 2022 | $71,000 | +208.7% | 58,392 | +447.8% | 0.02% | +120.0% |
Q1 2022 | $23,000 | – | 10,659 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 2,320,381 | $1,733,325 | 0.92% |
TANG CAPITAL MANAGEMENT LLC | 3,329,048 | $2,486,799 | 0.35% |
Vivo Capital, LLC | 3,547,030 | $2,649,631 | 0.29% |
Pivotal bioVenture Partners Investment Advisor LLC | 743,215 | $555,182 | 0.22% |
Newtyn Management, LLC | 920,000 | $687,240 | 0.17% |
SILVERARC CAPITAL MANAGEMENT, LLC | 631,887 | $472,020 | 0.14% |
EcoR1 Capital, LLC | 3,948,360 | $2,949,425 | 0.10% |
HHLR ADVISORS, LTD. | 2,309,764 | $1,725,394 | 0.04% |
Baker Brothers Advisors | 2,076,400 | $1,551,071 | 0.01% |
HARBOURVEST PARTNERS LLC | 18,783 | $14,031 | 0.01% |